ロード中...
MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support this approach. Here we describe a cohort of patien...
保存先:
| 出版年: | Mol Cancer Ther |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6363831/ https://ncbi.nlm.nih.gov/pubmed/30425131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0510 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|